Abstracts Archive - Page 866 of 2425 - ACR Meeting Abstracts

Abstract Number: 1614 • 2019 ACR/ARP Annual Meeting
Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience
Gabriela Garcia-Guevara¹, Francisco Treviño-Tello ², Christopher Cabib ¹, Irazú Contreras-Yáñez ³, Erwin Chiquete ⁴, Ariadna Díaz-Mora ¹, Yuliana Fernandez-Nicoli ⁴, Julio Macias-Gallardo ⁵, Juan José Gómez-Piña ⁴, Ivonne Sandoval-Flores ⁴ and Hilda Fragoso-Loyo ⁶, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
Background/Purpose: The prevalence of peripheral neurological manifestations in Systemic Lupus Erythematosus (SLE) ranges between 1.5% and 27% and are a major cause of morbidity.To determine…
Abstract Number: 1615 • 2019 ACR/ARP Annual Meeting
The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement
Yoshiyuki Arinuma ¹, Yasuhiro Hasegawa ¹, Takumi Muramatsu¹, Yu Matsueda ¹ and Kunihiro Yamaoka ¹, ¹Department of Rheumatology and Infectious Diseaes, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Background/Purpose: Autoantibodies against N-methyl-D-aspartate receptor subunit GluN2 (anti-GluN2) in the cerebrospinal fluid are known to be related with the development of diffuse psychiatric/neuropsychological manifestations in…
Abstract Number: 1616 • 2019 ACR/ARP Annual Meeting
Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?
Leyre Riancho-Zarrabeitia¹, Víctor M Martinez-Taboada ², Iñigo Rua Figueroa ³, Fernando Alonso ⁴, María Galindo ⁵, Juan Ovalles-Bonilla ⁶, Alejandro Olivé-Marqués ⁷, Antonio Fernández-Nebro ⁸, Jaime Calvo-Alen ⁹, Raul Menor Almagro ¹⁰, Eva Tomero-Muriel ¹¹, Esther Uriarte Isacelaya ¹², Alina Boteanu ¹³, Mariano Andrés ¹⁴, Mercedes Freire González ¹⁵, Gregorio Santos Soler ¹⁶, Esther Ruiz Lucea ¹⁷, Monica Ibañez Barcelo ¹⁸, Ivan Castellvi ¹⁹, Carles Galisteo ²⁰, Víctor Quevedo Vila ²¹, Enrique Raya ²², Javier Narváez ²³, Lorena Expósito ²⁴, José A Hernández-Beriain ²⁵, Loreto Horcada Rubio ²⁶, Elena Aurrecoechea ²⁷ and Jose Maria Pego-Reigosa ²⁸, ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Valdecilla, Santander, ³Hospital Doctor Negrin, Las Palmas, ⁴Unidad Investigación SER, Madrid, Spain, ⁵Hospital 12 De Octubre, Madrid, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital German Trias i Pujol, Badalona, Spain, ⁸Hospital Carlos Haya, Malaga, Spain, ⁹Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ¹⁰Hospital Universitario de Jerez, Puerto De Santa María, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Hospital Universitario Donosti, San Sebastian, Spain, ¹³Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Hospital Universitario Basurto, Bilbao, Spain, ¹⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Parc Taulí, Barcelona, Catalonia, Spain, ²¹Hospital Comarcal Monforte, Monforteº, Spain, ²²Hospital Universitario Clínico San Cecilio, Granada, Spain, ²³Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ²⁴Hospital Universitario de Canarias, Las Palmas, Spain, ²⁵Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, ²⁶Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁷Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²⁸Complexo Hospitalario Universitario, Vigo, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim is to investigate the association between the…
Abstract Number: 1617 • 2019 ACR/ARP Annual Meeting
Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus
Yevgeniya Gartshteyn¹, Adam Mor ², Laura Geraldino ², Teja Kapoor ², Tommy Chen ², Thierry Dervieux ³ and Anca Askanase ⁴, ¹Columbia University School of Medicine, Glen Rock, NJ, ²Columbia University School of Medicine, New York, NY, ³Exagen, Vista, CA, ⁴Columbia University, New York
Background/Purpose: Cell-bound complement activation products (CB-CAPs), including platelet bound C4d (PC4d), are sensitive markers for diagnosis and evaluation of lupus activity. Presence of PC4d is…
Abstract Number: 1618 • 2019 ACR/ARP Annual Meeting
Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity
Diane Apostolopoulos¹, Rangi Kandane-Rathnayake ¹, Worawit Louthrenoo ², Shue Fen Luo ³, Yeong-Jian Wu ³, Aisha Lateef ⁴, Vera Golder ¹, Sargunan Sockalingam ⁵, Sandra Navarra ⁶, Leonid Zamora ⁷, Laniyati Hamijoyo ⁸, Yasuhiro Katsumata ⁹, Masayoshi Harigai ⁹, Madelynn Chan ¹⁰, Sean O'Neill ¹¹, Fiona Goldblatt ¹², Chak Sing Lau ¹³, Alberta Hoi ¹⁴, Mandana Nikpour ¹⁵ and Eric Morand ¹⁶, ¹Monash University, Melbourne, Australia, ²Chiang Mai University Hospital, Chiang Mai, Thailand, ³Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁴National University Hospital, Singapore, Singapore, ⁵University of Malaya, Kuala Lumpur, Malaysia, ⁶University of Santo Tomas Hospital, Manila, Philippines, ⁷Santo Tomas Hospital, Manila, Philippines, ⁸Padjadjaran University, Bandung, Indonesia, ⁹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹⁰Tan Tock Seng Hospital, Singapore, Singapore, ¹¹University of NSW, Ingham Institute of Applied Medical Research, Sydney, Australia, ¹²Royal Adelaide Hospital, Adelaide, Australia, ¹³Hong Kong University, Hong Kong, Hong Kong, ¹⁴School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ¹⁵St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia, ¹⁶Monash University, Melbourne, Victoria, Australia
Background/Purpose: Accrual of irreversible organ damage is a major risk factor for death in SLE. While unmodifiable factors, such as age at disease onset and…
Abstract Number: 1619 • 2019 ACR/ARP Annual Meeting
Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study
Viola Signorini¹, Dina Zucchi ², Chiara Tani ³, Rosa Maria Bruno ⁴, Elena Elefante ³, Chiara Stagnaro ⁵, Linda Carli ³, Alice Parma ³, Francesco Ferro ⁶, Sabina Armenia ⁷, lorenzo Ghiadoni ⁸, Stefano Taddei ⁷ and Marta Mosca ³, ¹Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Toscana, Italy, ²Rheumatology Unit. Department of clinical and experimental medicine, University of PIsa, Pisa, Toscana, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Hypertension Unit, Department of clinical e experimental medicine, University di Pisa, Pisa, Italy, ⁵Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁷Hypertension Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy, ⁸Emergency Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy
Background/Purpose: Systemic Lupus Erithematosus (SLE) is associated with increased cardiovascular (CV) risk compared with general population; an accelerated atherosclerosis is considered the main underlying mechanism.…
Abstract Number: 1620 • 2019 ACR/ARP Annual Meeting
T-cell Exhaustion in Prolonged Remission SLE Patients
Francisco Treviño-Tello¹, Guadalupe Lima ¹, Juan Jakez-Ocampo ², Luis Llorente ¹, Yemil Atisha-Fregoso ¹ and Hilda Fragoso-Loyo ³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
Background/Purpose: Cellular exhaustion is a cellular dysfunction characterized by the progressive loss of the effector function, and an increased expression of multiple inhibitory receptors. Exhaustion…
Abstract Number: 1621 • 2019 ACR/ARP Annual Meeting
The Impact of Disease Activity and Related Factors on Cognitive Dysfunction in SLE
Erik Anderson¹, Elisabeth Ploran ², Joseph Hong ³, Betty Diamond ⁴, Bruce Volpe ⁵, Cynthia Aranow ⁶ and Meggan Mackay ⁷, ¹Northwell Health System, Feinstein Institute for Medical Research, New York, ²Hofstra University, Hempstead, ³Northwell Health System, Feinstein Institute for Medical Research, Manhasset, ⁴Feinstein Institutes for Medical Research, Manhasset, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Manhasset, NY, ⁷Feinstein Institute for Medical Research, New York
Background/Purpose: Attribution of cognitive dysfunction (CD) to SLE is compromised by potential confounders. Studies reveal conflicting results on the relationship between CD and disease activity,…
Abstract Number: 1622 • 2019 ACR/ARP Annual Meeting
Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review
Sofia Alfred¹, Lina Khoja ¹, Melanie Anderson ², Zahi Touma ³ and Lisa Engel ⁴, ¹University of Toronto, Toronto, Canada, ²University Health Network, Toronto, Canada, ³University Health Network, University of Toronto, Toronto, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Approximately 33 to 43% of individuals with SLE experience cognitive impairments…
Abstract Number: 1623 • 2019 ACR/ARP Annual Meeting
Mortality in a SLE Inception Cohort of Hispanic Patients
Maria del Carmen Zamora Medina¹, Jessica Roldan Ortega ², Mario Cesar Ocampo Torres ³, Pilar Lara Reyes ¹, Ivon Bautista Mejia ¹, Alba Cicero Casarrubias ¹ and Juanita Romero-Diaz ⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, Mexico, ²Monterrey Institute of Technology and Higher Education, MEXICO CITY, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico
Background/Purpose: To determine mortality and identify risk factors for mortality at 10 years in a mexican-mestizo SLE inception cohort at a tertiary care center in…
Abstract Number: 1624 • 2019 ACR/ARP Annual Meeting
Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients
Maria del Carmen Zamora Medina¹, Jessica Roldan Ortega ², Mario Cesar Ocampo Torres ³, Pilar Lara Reyes ¹, Alba Cicero Casarrubias ¹, Ivon Bautista Mejia ¹ and Juanita Romero-Diaz ⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, Mexico, ²Monterrey Institute of Technology and Higher Education, MEXICO CITY, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico
Background/Purpose: The aims of our study were to determine the cumulative prevalence of damage at baseline, 5 years and 10 years of follow-up, to identify…
Abstract Number: 1625 • 2019 ACR/ARP Annual Meeting
Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities
Yu Deng ¹, Anh Chung ², Abel Kho ¹, Yuan Luo ¹, Rosalind Ramsey-Goldman ² and Theresa Walunas², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Lupus is a systemic autoimmune disease whose mechanism of development is largely unknown. Prior infection is a suspected sentinel event that may trigger disease…
Abstract Number: 1626 • 2019 ACR/ARP Annual Meeting
Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus
Mario Cesar Ocampo Torres ¹, Elizabeth Olivares-Martinez ² and Juanita Romero-Diaz³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico
Background/Purpose: Background/purpose Premature atherosclerosis has been recognized as a major cause of morbidity and mortality in SLE patients. We aimed to determine 1) the incidence…
Abstract Number: 1627 • 2019 ACR/ARP Annual Meeting
Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Chien-Chih Lai¹, Yi-Syuan Sun ¹ and Chang-Youh Tsai ², ¹Division of Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: To evaluate the pathogens from bronchoalveolar lavage fluid (BALF) and risk factors of mortality in SLE patients with pneumonia and respiratory failure.Methods: Twenty-four SLE…
Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Aryeh Fischer¹, Oliver Distler ², Dinesh Khanna ³, Yannick Allanore ⁴, Anna Maria Hoffmann-Vold ⁵, Gabriele Valentini ⁶, Toby Maher ⁷, Martin Aringer ⁸, Leslie Meng ⁹, Margarida Alves ¹⁰, Martina Gahlemann ¹¹, Manuel Quaresma ¹⁰ and Masataka Kuwana ¹², ¹University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ⁷National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].